Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims
CONCLUSION: Buprenorphine discontinuation is high across outpatient PCP, psychiatry, and SUD treatment facility settings, with potentially lower treatment retention among Medicaid enrollees receiving care from SUD facilities and PCPs.PMID:38493109 | PMC:PMC10943881 | DOI:10.1186/s13722-024-00450-0 (Source: Addiction Science and Clinical Practice)
Source: Addiction Science and Clinical Practice - March 17, 2024 Category: Addiction Authors: Kevin Y Xu Alex K Gertner Shelly F Greenfield Arthur Robin Williams Richard A Grucza Source Type: research
STS Database Analysis: Comparing Sublobar Techniques in Stage IA Lung Cancer
CONCLUSIONS: In clinical stage IA lung cancer, relative to segmentectomy, wedge resection has comparable overall survival and lower perioperative morbidity, suggesting it is an equally effective option for the broader population of patients with clinical-stage IA lung cancer, not only those at highest risk of complications.PMID:38493921 | DOI:10.1016/j.athoracsur.2024.03.008 (Source: The Annals of Thoracic Surgery)
Source: The Annals of Thoracic Surgery - March 17, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Christopher W Towe Maria V Grau-Sepulveda Matthew G Hartwig Lillian Kang Boxiang Jiang Jillian Sinopoli Leonidas Tapias Vargas Andrzej Kosinski Philip A Linden Source Type: research
Treatment setting and buprenorphine discontinuation: an analysis of multi-state insurance claims
CONCLUSION: Buprenorphine discontinuation is high across outpatient PCP, psychiatry, and SUD treatment facility settings, with potentially lower treatment retention among Medicaid enrollees receiving care from SUD facilities and PCPs.PMID:38493109 | PMC:PMC10943881 | DOI:10.1186/s13722-024-00450-0 (Source: Addiction Science and Clinical Practice)
Source: Addiction Science and Clinical Practice - March 17, 2024 Category: Addiction Authors: Kevin Y Xu Alex K Gertner Shelly F Greenfield Arthur Robin Williams Richard A Grucza Source Type: research
Deception by Obfuscation: Studnicki et al. ’s retracted longitudinal cohort study of emergency room utilization following abortion
In November 2022, the anti-abortion advocacy group, Alliance for Hippocratic Medicine filed a lawsuit against the U.S. Food and Drug Administration challenging the initial 2000 approval of mifepristone and its subsequent approvals, which removed unnecessary restrictions on its use, by disputing the medication ’s safety record. Such challenges relied on a study examining the incidence of emergency room (ER) visits following medication abortion with mifepristone and procedural abortion using Medicaid claims data from 1999–2015. (Source: Contraception)
Source: Contraception - March 15, 2024 Category: OBGYN Authors: Ushma D. Upadhyay, Chris E. Adkins Source Type: research
Association of Medicaid Reimbursement Policies with Provision of Long-Acting Reversible Contraception in the Postpartum Period, 2012 –2018
Journal of Women's Health, Ahead of Print. (Source: Journal of Women)
Source: Journal of Women - March 15, 2024 Category: OBGYN Authors: Kyle J. Moon Lenisa V. Chang Ian Bryant Kathryn A. Hasenstab Alison H. Norris Saira Nawaz Source Type: research
Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome
Alzheimers Dement. 2024 Mar 13. doi: 10.1002/alz.13778. Online ahead of print.ABSTRACTPrior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease. This overlooks adults with Down syndrome (DS), who often experience dementia at a younger age and with different diagnostic assessment outcomes. This exclusion may deny DS adults access to potential disease-modifying treatments. To address this issue, an international expert p...
Source: The Journal of Alzheimers Association - March 14, 2024 Category: Psychiatry Authors: Hampus Hillerstrom Richard Fisher Matthew P Janicki Brian Chicoine Bradley T Christian Anna Esbensen Lucille Esralew Juan Fortea Sigan Hartley Jason Hassenstab Seth M Keller Sharon Krinsky-McHale Florence Lai Johannes Levin Mary McCarron Eric McDade Anne Source Type: research
Comparative Risk of Injury with Concurrent Use of Opioids and Skeletal Muscle Relaxants
In conclusion, the relative injury rate associated with different SMRs used concurrently with the three most dispensed opioids appears to vary depending on the specific opioid and the order of combination initiation. If confirmed by future studies, clinicians should consider the varying injury rates when prescribing SMRs to individuals using hydrocodone, oxycodone, and tramadol.PMID:38482733 | DOI:10.1002/cpt.3248 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - March 14, 2024 Category: Drugs & Pharmacology Authors: Cheng Chen Sean Hennessy Colleen M Brensinger Todd A Miano Warren B Bilker Sascha Dublin Sophie P Chung John R Horn Anika Tiwari Charles E Leonard Source Type: research
Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome
Alzheimers Dement. 2024 Mar 13. doi: 10.1002/alz.13778. Online ahead of print.ABSTRACTPrior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease. This overlooks adults with Down syndrome (DS), who often experience dementia at a younger age and with different diagnostic assessment outcomes. This exclusion may deny DS adults access to potential disease-modifying treatments. To address this issue, an international expert p...
Source: The Journal of Alzheimers Association - March 14, 2024 Category: Psychiatry Authors: Hampus Hillerstrom Richard Fisher Matthew P Janicki Brian Chicoine Bradley T Christian Anna Esbensen Lucille Esralew Juan Fortea Sigan Hartley Jason Hassenstab Seth M Keller Sharon Krinsky-McHale Florence Lai Johannes Levin Mary McCarron Eric McDade Anne Source Type: research
Incidence of pneumococcal disease in children ≤48 months old in the United States: 1998-2019
CONCLUSIONS: Incidence rates of IPD, ACP, and AOM decreased in children with commercial insurance and Medicaid coverage from 1998 to 2019. However, burden of disease remained substantial, with higher annual IRs for IPD and ACP for Medicaid-insured vs. commercially-insured children. IPD and inpatient ACP were most common in the youngest children 0-6 months old, followed by the 7-12-month age group.PMID:38485640 | DOI:10.1016/j.vaccine.2024.03.013 (Source: Vaccine)
Source: Vaccine - March 14, 2024 Category: Allergy & Immunology Authors: Salini Mohanty Nicolae Done Qing Liu Yan Song Travis Wang Katherine Gaburo Eric M Sarpong Meghan White Jessica P Weaver James Signorovitch Thomas Weiss Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Comparative Risk of Injury with Concurrent Use of Opioids and Skeletal Muscle Relaxants
In conclusion, the relative injury rate associated with different SMRs used concurrently with the three most dispensed opioids appears to vary depending on the specific opioid and the order of combination initiation. If confirmed by future studies, clinicians should consider the varying injury rates when prescribing SMRs to individuals using hydrocodone, oxycodone, and tramadol.PMID:38482733 | DOI:10.1002/cpt.3248 (Source: Clinical Pharmacology and Therapeutics)
Source: Clinical Pharmacology and Therapeutics - March 14, 2024 Category: Drugs & Pharmacology Authors: Cheng Chen Sean Hennessy Colleen M Brensinger Todd A Miano Warren B Bilker Sascha Dublin Sophie P Chung John R Horn Anika Tiwari Charles E Leonard Source Type: research
Adapting prescribing criteria for amyloid-targeted antibodies for adults with Down syndrome
Alzheimers Dement. 2024 Mar 13. doi: 10.1002/alz.13778. Online ahead of print.ABSTRACTPrior authorization criteria for Federal Drug Administration (FDA) approved immunotherapeutics, among the class of anti-amyloid monoclonal antibodies (mAbs), established by state drug formulary committees, are tailored for adults with late-onset Alzheimer's disease. This overlooks adults with Down syndrome (DS), who often experience dementia at a younger age and with different diagnostic assessment outcomes. This exclusion may deny DS adults access to potential disease-modifying treatments. To address this issue, an international expert p...
Source: The Journal of Alzheimers Association - March 14, 2024 Category: Psychiatry Authors: Hampus Hillerstrom Richard Fisher Matthew P Janicki Brian Chicoine Bradley T Christian Anna Esbensen Lucille Esralew Juan Fortea Sigan Hartley Jason Hassenstab Seth M Keller Sharon Krinsky-McHale Florence Lai Johannes Levin Mary McCarron Eric McDade Anne Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
Commercial Versus Medicaid Insurance and Use of High-Priced Anticancer Treatments
CONCLUSIONS: Individuals with Medicaid and commercial insurance received high-priced treatments in similar proportion, after accounting for differences in case mix. However, modification by provider characteristics suggests that insurance type may influence treatment selection for some patient groups. Further work is needed to determine the relationship between insurance status and newer, high-price drugs such as immune-oncology agents.PMID:38484395 | DOI:10.1093/oncolo/oyae035 (Source: The Oncologist)
Source: The Oncologist - March 14, 2024 Category: Cancer & Oncology Authors: Aaron P Mitchell Alan C Kinlaw Sharon Peacock-Hinton Stacie B Dusetzina Aaron N Winn Hanna K Sanoff Jennifer L Lund Source Type: research
State Medicaid Coverage and Reimbursement of Antiobesity Medications
This study examines state Medicaid coverage policies for antiobesity medications and their trends in Medicaid reimbursement from 2011 to 2022. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - March 14, 2024 Category: General Medicine Source Type: research
